IL270685B - Cleavable derivatives of lipoglycopeptide and their uses - Google Patents

Cleavable derivatives of lipoglycopeptide and their uses

Info

Publication number
IL270685B
IL270685B IL270685A IL27068519A IL270685B IL 270685 B IL270685 B IL 270685B IL 270685 A IL270685 A IL 270685A IL 27068519 A IL27068519 A IL 27068519A IL 270685 B IL270685 B IL 270685B
Authority
IL
Israel
Prior art keywords
infection
further embodiment
pharmaceutical composition
acid
glycopeptide
Prior art date
Application number
IL270685A
Other languages
English (en)
Hebrew (he)
Other versions
IL270685A (enExample
Inventor
Ryan Heckler
Donna Konicek
Adam Plaunt
Vladimir Malinin
Walter Perkins
Original Assignee
Insmed Inc
Ryan Heckler
Donna Konicek
Adam Plaunt
Vladimir Malinin
Walter Perkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insmed Inc, Ryan Heckler, Donna Konicek, Adam Plaunt, Vladimir Malinin, Walter Perkins filed Critical Insmed Inc
Publication of IL270685A publication Critical patent/IL270685A/he
Publication of IL270685B publication Critical patent/IL270685B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL270685A 2017-05-22 2018-05-22 Cleavable derivatives of lipoglycopeptide and their uses IL270685B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762509378P 2017-05-22 2017-05-22
US201762518280P 2017-06-12 2017-06-12
US201762560413P 2017-09-19 2017-09-19
PCT/US2018/033963 WO2018217808A1 (en) 2017-05-22 2018-05-22 Lipo-glycopeptide cleavable derivatives and uses thereof

Publications (2)

Publication Number Publication Date
IL270685A IL270685A (enExample) 2019-12-31
IL270685B true IL270685B (en) 2022-09-01

Family

ID=64395938

Family Applications (2)

Application Number Title Priority Date Filing Date
IL270685A IL270685B (en) 2017-05-22 2018-05-22 Cleavable derivatives of lipoglycopeptide and their uses
IL270686A IL270686B (en) 2017-05-22 2018-05-22 Derivatives of glycopeptides and their uses

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL270686A IL270686B (en) 2017-05-22 2018-05-22 Derivatives of glycopeptides and their uses

Country Status (12)

Country Link
US (3) US20200368312A1 (enExample)
EP (2) EP3630154A4 (enExample)
JP (2) JP7210476B2 (enExample)
KR (2) KR102661790B1 (enExample)
CN (2) CN110996984A (enExample)
AU (2) AU2018273887B2 (enExample)
BR (2) BR112019024549A2 (enExample)
CA (2) CA3062570A1 (enExample)
GB (2) GB2577420B (enExample)
IL (2) IL270685B (enExample)
NZ (2) NZ758839A (enExample)
WO (2) WO2018217808A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008143889A1 (en) 2007-05-14 2008-11-27 Research Foundation Of State University Of New York Induction of a physiological dispersion response in bacterial cells in a biofilm
CA3062570A1 (en) * 2017-05-22 2018-11-29 Insmed Incorporated Lipo-glycopeptide cleavable derivatives and uses thereof
NL2023883B1 (en) * 2019-09-24 2021-04-26 Univ Leiden Antibiotic compounds
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2023094994A1 (en) * 2021-11-24 2023-06-01 Cumberland Pharmaceuticals Inc Methods for the prevention or treatment of anthrax infection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009042187A1 (en) * 2007-09-25 2009-04-02 Nektar Therapeutics Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin
CN105085636A (zh) * 2014-05-19 2015-11-25 中国医学科学院药物研究所 一类万古霉素衍生物、其制备方法及其在抗菌方面的应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639433A (en) 1985-08-14 1987-01-27 Eli Lilly And Company Glycopeptide derivatives
PT86457B (pt) * 1986-12-30 1990-11-20 Smithkline Beecham Corp Processo para a preparacao de glicopeptidos glicosilados e de composicoes que os contem
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
PT101450B (pt) 1994-02-02 1999-11-30 Hovione Produtos Farmaceuticos Novo dispositivo para inalacao
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
AU5806898A (en) 1996-12-31 1998-07-31 Inhale Therapeutic Systems Processes and compositions for spray drying hydrophobic drugs in organic solventsuspensions of hydrophilic excipients
WO1999016420A1 (en) 1997-09-29 1999-04-08 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in nebulizers
NZ503464A (en) 1997-09-29 2002-05-31 Inhale Therapeutic Syst Perforated microparticles containing a bioactive agent for pulmonary delivery
US6518242B1 (en) * 1998-02-20 2003-02-11 Theravance, Inc. Derivatives of glycopeptide antibacterial agents
EP1085846A2 (en) * 1998-06-08 2001-03-28 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
UA73924C2 (en) 1998-10-09 2005-10-17 Nektar Therapeutics Device for delivering active agent formulation to lungs of human patient
ES2201825T3 (es) 1998-12-23 2004-03-16 Theravance, Inc. Derivados del glicopeptidos y composiciones farmaceuticas que los contienen.
JP4377076B2 (ja) 1999-05-28 2009-12-02 ネクター セラピューティクス 噴霧化された薬物の計量された量を投与する装置と方法
US6606992B1 (en) 1999-06-30 2003-08-19 Nektar Therapeutics Systems and methods for aerosolizing pharmaceutical formulations
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
WO2001057071A2 (en) 2000-02-04 2001-08-09 Advanced Medicine, Inc. Glycopeptide derivatives having antibiotic activity
WO2001058933A2 (en) 2000-02-11 2001-08-16 Eli Lilly And Company Selective n-acylation of a82846 glycopeptide analogs
CA2382133C (en) 2000-05-10 2010-11-23 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
UA75083C2 (uk) 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
TWI312785B (en) * 2001-08-24 2009-08-01 Theravance Inc Process for preparing vancomycin derivatives
US7273845B2 (en) 2002-11-12 2007-09-25 Enzon Pharmaceuticals, Inc. Polymeric prodrugs of vancomycin
JP2006528704A (ja) 2003-05-27 2006-12-21 セラヴァンス インコーポレーテッド グリコペプチド抗細菌剤と組み合わせたポリエンマクロライド抗真菌剤の使用
TWI342312B (en) * 2003-10-22 2011-05-21 Theravance Inc Hydrochloride salts of a glycopeptide phosphonate derivative
US7632918B2 (en) * 2005-02-28 2009-12-15 Novartis Vaccines And Diagnostics, Inc. Semi-synthetic glycopeptides with antibiotic activity
US20070185015A1 (en) * 2005-02-28 2007-08-09 Chiron Corporation and North China Pharmaceutical Corporation Semi-synthetic desmethyl-vancomycin-based glycopeptides with antibiotic activity
EP2214645A4 (en) * 2007-10-23 2013-09-25 Transave Inc LIPOSOMAL VANCOMYCIN PREPARATIONS
WO2009085562A1 (en) * 2007-12-26 2009-07-09 Lead Therapeutics, Inc. Novel semi-synthetic glycopeptides as antibacterial agents
WO2010048340A2 (en) * 2008-10-24 2010-04-29 Lead Therapeutics, Inc. Novel semi-synthetic glycopeptides as antibacterial agents
GB2465863A (en) * 2008-12-05 2010-06-09 Lead Therapeutics Inc Semi-synthetic heptapeptidic glycopeptides for the treatment of bacterial infections
JP2012522009A (ja) * 2009-03-26 2012-09-20 パルマトリックス，インコーポレイテッド 肺炎および人工呼吸器関連気管気管支炎を治療および予防するための方法
CN102573882A (zh) * 2009-04-28 2012-07-11 塔尔甘塔治疗公司 用奥利万星治疗细菌感染的方法
BR112013029803B1 (pt) * 2011-05-19 2021-07-13 Savara, Inc Composições de vancomicina em pó seco
US9572774B2 (en) * 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
JP6254525B2 (ja) 2011-08-05 2017-12-27 ザ スクリプス リサーチ インスティテュート バンコマイシン耐性菌株に対して有効なグリコペプチド系抗生物質類似体
CN104349783B (zh) * 2012-05-21 2018-07-13 英斯麦德公司 治疗肺部感染的系统
WO2014085526A1 (en) 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
GB201402267D0 (en) * 2014-02-10 2014-03-26 Cambridge Entpr Ltd Antibacterial agents
US10577395B2 (en) 2014-07-10 2020-03-03 The Scripps Research Institute N-(hydrophobe-substituted) vancosaminyl [Ψ-[C(=NH) NH] Tpg4] vancomycin and [Ψ-[CH2NH]Tpg4] vancomycin
CN107325159A (zh) 2016-04-29 2017-11-07 中国科学院上海药物研究所 一类万古霉素衍生物、其制备方法、药物组合物和用途
WO2018008197A1 (ja) 2016-07-07 2018-01-11 日東電工株式会社 反射層および蛍光体層付光半導体素子
JP7104424B2 (ja) 2016-10-31 2022-07-21 ザ スクリプス リサーチ インスティテュート 相乗的に抗菌効力及び耐久性を改善するポケット再設計バンコマイシン類似体への末梢修飾
CA3062570A1 (en) 2017-05-22 2018-11-29 Insmed Incorporated Lipo-glycopeptide cleavable derivatives and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009042187A1 (en) * 2007-09-25 2009-04-02 Nektar Therapeutics Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin
CN105085636A (zh) * 2014-05-19 2015-11-25 中国医学科学院药物研究所 一类万古霉素衍生物、其制备方法及其在抗菌方面的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M. J. DE JESUS VALLE ET AL,, PULMONARY VERSUS SYSTEMIC DELIVERY OF ANTIBIOTICS: COMPARISON OF VANCOMYCIN DISPOSITIONS IN THE ISOLATED RAT LUNG, 6 August 2007 (2007-08-06) *

Also Published As

Publication number Publication date
NZ758839A (en) 2025-08-29
EP3634464A1 (en) 2020-04-15
US20200368312A1 (en) 2020-11-26
WO2018217800A1 (en) 2018-11-29
JP2020520987A (ja) 2020-07-16
CN110891590B (zh) 2023-07-18
NZ758836A (en) 2025-11-28
AU2018273887B2 (en) 2022-09-08
WO2018217808A1 (en) 2018-11-29
GB2577419A (en) 2020-03-25
CA3062570A1 (en) 2018-11-29
AU2018271873B2 (en) 2023-11-02
GB201917677D0 (en) 2020-01-15
EP3630154A4 (en) 2021-03-10
CN110891590A (zh) 2020-03-17
US11857597B2 (en) 2024-01-02
CN110996984A (zh) 2020-04-10
JP7210476B2 (ja) 2023-01-23
AU2018273887A1 (en) 2019-11-28
KR20200027922A (ko) 2020-03-13
GB2577420B (en) 2022-07-06
US20220133843A1 (en) 2022-05-05
GB2577420A (en) 2020-03-25
BR112019024549A2 (pt) 2020-06-09
KR102661786B1 (ko) 2024-04-26
JP2020520986A (ja) 2020-07-16
AU2018271873A1 (en) 2019-11-28
BR112019024472A2 (pt) 2020-06-16
CA3062567A1 (en) 2018-11-29
GB2577419B (en) 2022-08-17
KR102661790B1 (ko) 2024-04-26
EP3630154A1 (en) 2020-04-08
EP3634464A4 (en) 2021-04-07
US11071769B2 (en) 2021-07-27
IL270686B (en) 2022-09-01
GB201917675D0 (en) 2020-01-15
JP7165146B2 (ja) 2022-11-02
IL270685A (enExample) 2019-12-31
KR20200026803A (ko) 2020-03-11
US20200155640A1 (en) 2020-05-21
IL270686A (enExample) 2019-12-31

Similar Documents

Publication Publication Date Title
US11857597B2 (en) Lipo-glycopeptide cleavable derivatives and uses thereof
CN101222927B (zh) 气溶胶化的氟喹诺酮类药物及其应用
JP2008500965A (ja) 細菌の排出ポンプ阻害剤の使用および投与
US20220024980A1 (en) Lipo-glycopeptide cleavable derivatives and uses thereof
CA3217735A1 (en) Methods for treating a pulmonary disease with an alk-5 (tgf beta r1) inhibitor
WO2022198009A1 (en) Dry powder compositions of glycopeptide derivative compounds and methods of use thereof
US20210388028A1 (en) Glycopeptide derivative compounds and uses thereof
EP4306130A1 (en) Inhalable formulation for use in the treatment of bacterial lung infections